论文部分内容阅读
Ｐｈ染色体是慢性粒细胞白血病（ＣＭＬ）的细胞遗传学标记，而ｂｃｒ／ａｂｌ基因重排则为ＣＭＬ的分子基础。ＢＣＲ、ｃ－ａｂｌ基因重排及ｂｃｒ／ａｂｌ嵌合基因的结构，转录和表达是ＣＭＬ发病的关键环节．随着分子生物学技术的迅猛发展，对ｂｃｒ／ａｂｌ重组基因的研究日益深入有可能最终阐明ＣＭＬ的发病机制，并在临床上对ＣＭＬ诊断、分型、鉴别、预后判断及治疗等均有极其重要的指导意义．目前已在尝试利用分子生物学技术在基因水平根治ＣＭＬ，这项技术为治疗ＣＭＬ开辟了一条新途径。
The Ph chromosome is a cytogenetic marker of chronic myeloid leukemia (CML), whereas the bcr / abl gene rearrangement is the molecular basis of CML. BCR, c-abl gene rearrangement and bcr / abl chimeric gene structure, transcription and expression of CML is the key link in the pathogenesis. With the rapid development of molecular biology technology, the research on bcr / abl recombination gene is more and more likely to finally elucidate the pathogenesis of CML and clinically the diagnosis, classification, identification, prognosis and treatment of CML clinically Important guiding significance. At present, attempts have been made to use molecular biology techniques to cure CML at the gene level, which opens up a new way for treating CML.